VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Chimerix Executive Compensation (FY23)

CMRX · Executive and director compensation, fiscal 2022 to 2023
Chief executive, fiscal 2023
◇
Mike Andriole
Latest say-on-pay support
=
June 20, 2024
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Chimerix brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of October 25, 2026Latest filing (8-K): June 21, 2024
4 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Chimerix brief$500Get the executive brief
Velarion Intel, one year, every company
129 figures on this page: 126 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Mike Andriole: $1,672,620 → $1,312,421 (21.5% lower)
Say-on-pay support: 78.0% → 83.0% (5.0 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Chimerix's chief executive and what were they paid?
Mike Andriole was paid $1,312,421 in total compensation as President and Chief Executive Officer for fiscal 2023. Compared with the $1,672,620 reported for fiscal 2022, Andriole's total was 21.5% lower.
What was Chimerix's say-on-pay result?
Shareholders supported the say-on-pay proposal with 83.0% of votes cast for or against in favor at the meeting held June 20, 2024 for fiscal 2023.
Which companies are in Chimerix's peer group?
The disclosed peer group includes Allovir, ALX Oncology, Arcturus Therapeutics, Ardelyx and BioXcel Therapeutics, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mike Sherman
President and Chief Executive Officer
◇——◇◇—◇◇
Mike Andriole
Chief Business Officer and Chief Financial Officer
◇——◇◇—◇◇
Allen Melemed
Chief Medical Officer
◇——◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mike Sherman
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Mike Andriole
President and Chief Executive Officer
◇—◇◇◇—◇◇
Allen Melemed
Chief Medical Officer
◇—◇◇◇—◇◇
Michael Alrutz
Senior Vice President, General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
On AugOptions/SARs———◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Mike ShermanOption◇—◇1/17/2032
Option◇—◇1/16/2033
Option◇—◇1/21/2031
RSU◇◇——
Option◇—◇1/20/2030
Mike AndrioleOption◇—◇1/17/2032
Option◇—◇7/31/2033
Option◇—◇1/16/2033
Option◇—◇1/21/2031
RSU◇◇——
RSU◇◇——
Option◇—◇1/20/2030
Allen MelemedOption◇—◇1/17/2032
Option◇—◇1/16/2033
Option◇—◇1/21/2031
Option◇—◇6/18/2030
RSU◇◇——
Michael AlrutzOption◇—◇1/17/2032
Option◇—◇1/16/2033
Option◇—◇1/21/2031
RSU◇◇——
Option◇—◇1/20/2030
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2023
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Martha J. Demski
Lead independent director
◇—◇———◇
Patrick Machado
◇—◇———◇
Fred A. Middleton
◇—◇———◇
Robert J. Meyer
◇—◇———◇
Vicki Vakiener
◇—◇———◇
Catherine L. Gilliss
◇—◇———◇
Pratik S. Multani
◇—◇———◇
Lisa L. Decker
——◇———◇
Mike Andriole, Marc D. Kozin and Mike Sherman served on the board in fiscal 2023 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
  • Allovir ALVR
  • ALX Oncology ALXO
  • Arcturus Therapeutics ARCT
  • Ardelyx ARDX
  • BioXcel Therapeutics BTAI
  • Curis CRIS
  • CymaBay Therapeutics CBAY
  • CytomX Therapeutics CTMX
  • G1 Therapeutics GTHX
  • Gritstone bio GRTS
  • Jounce Therapeutics symbol not shown
  • MEI Pharma MEIP
  • Precision BioSciences DTIL
  • Seres Therapeutics MCRB
  • Trevena TRVN
  • VBI Vaccines VBIV
  • Y-mAbs Therapeutics YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2023June 20, 2024=◇◇◇
2022June 9, 2023=◇◇◇
2021June 23, 2022=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Mike Andriole (President and Chief Executive Officer), FY2023 total compensation $1,312,421 (base salary $528,473) [exec_comp, SEC accession 0001117480-24-000010, filed 2024-04-26]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Chimerix files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Chimerix disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Chimerix sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Chimerix's disclosed peer group is defensible, who names Chimerix back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
129 figures on this page: 126 cited to the filing that reported them, 3 calculated from figures it prints.
126 cited to the filing
3 calculated from the filing

Documents cited

  1. 0001104659-24-073907
    Proposal 4: Approval, on an advisory basis, of the compensation of the Company’s named executive officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s n
  2. 0001117480-24-000010
    EXECUTIVE AND DIRECTOR COMPENSATION EXECUTIVE COMPENSATION
  3. 0001104659-23-070155
    Proposal 3: Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers The Company’s stockholders approved, on a non-binding, advisory basis, the compens
  4. 0001117480-22-000027
    Proposal 3: Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers The Company’s stockholders approved, on a non-binding, advisory basis, the compens
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Chimerix executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/CMRX (accessed 2026).
Short form: data: Velarion

The Chimerix brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Chimerix and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Chimerix discloses

The companies named in CMRX's own disclosed peer group.

ALX OncologyArcturus TherapeuticsArdelyxCurisCytomX TherapeuticsG1 TherapeuticsPrecision BioSciencesSeres TherapeuticsY-mAbs Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy